Summary: Zenas BioPharma director Lu Hongbo acquired 3,768 shares on March 31, 2026, at $18.63 per share, for a transaction value of $70,197. The purchase comes as the stock has posted a 155% gain over the past year but remains down 41% year-to-date. InvestingPro analysis indicates the share price currently appears overvalued versus its Fair Value estimate.
Insider transaction details
According to the filing, Lu Hongbo's purchase was executed at $18.63 a share. After the acquisition, Lu indirectly holds 426,736 shares in Zenas BioPharma. The company's shares are trading at $21.41 at the time of reporting, which is above the director's purchase price.
Recent financing activity
Zenas BioPharma recently priced two public offerings, raising $200 million through convertible senior notes and $100 million via a stock sale. The convertible senior notes mature in 2032, carry a 2.50% interest rate and have a conversion price of approximately $26.50 per share.
Separately, Morgan Stanley noted that the company extended its cash runway through a new $250 million debt facility with Pharmakon. Analyst actions accompanying the financing included Guggenheim increasing its price target to $55 and maintaining a Buy rating, while Morgan Stanley set a $21 price target and kept an Equalweight rating.
Clinical progress
Zenas BioPharma reported promising Phase 2 results for its experimental multiple sclerosis therapy, obexelimab. In the MoonStone trial for Relapsing Multiple Sclerosis, obexelimab achieved a 95% reduction in brain lesions compared to placebo and met the study's primary endpoint, demonstrating a significant reduction in inflammation markers.
The company is progressing toward regulatory filings, planning to submit a biologics license application for obexelimab in the second quarter of 2026 and to file a marketing authorization application in the second half of 2026.
Context and implications
The insider purchase, paired with recent financing and clinical milestones, highlights active corporate and capital-market developments at Zenas BioPharma. While the director's purchase price is below the current market quote, third-party valuation analysis cited in the filing suggests the shares may be trading above fair value.
These combined elements - insider buying, analyst coverage adjustments, new financing arrangements and positive clinical data - form the immediate backdrop for investor assessment of the company's near-term prospects.